Markus Warmuth

Markus brings over 20 years of experience in data-driven drug discovery and precision medicine to Monte Rosa Therapeutics. He joined Monte Rosa Therapeutics from Third Rock Ventures, where he worked as an Entrepreneur-in-Residence and played an integral role in the venture capital firm’s formation of new biotech companies. Prior to his role at Third Rock Ventures, Markus spent seven years as the Chief Executive Officer of H3 Biomedicine, a biopharmaceutical company that specializes in the discovery and development of genomics-based precision oncology treatments. Markus has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. He also currently serves as a Venture Partner at Versant Ventures. He earned his M.D. from Ludwig Maximilian University, in Munich, Germany, and currently resides in Boston, MA.